<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39352225</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-3907</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of proteome research</Title><ISOAbbreviation>J Proteome Res</ISOAbbreviation></Journal><ArticleTitle>Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jproteome.2c00422</ELocationID><Abstract><AbstractText>Circulating proteomes provide a snapshot of the physiological state of a human organism responding to pathogenic challenges and drug interventions. The outcomes of patients with COVID-19 and acute respiratory distress syndrome triggered by the SARS-CoV2 virus remain uncertain. Tocilizumab is an anti-interleukin-6 treatment that exerts encouraging clinical activity by controlling the cytokine storm and improving respiratory distress in patients with COVID-19. We investigate the biological determinants of therapeutic outcomes after tocilizumab treatment. Overall, 28 patients hospitalized due to severe COVID-19 who were treated with tocilizumab intravenously were included in this study. Sera were collected before and after tocilizumab, and the patient's outcome was evaluated until day 30 post-tocilizumab infusion for favorable therapeutic response to tocilizumab and mortality. Hyperreaction monitoring measurements by liquid chromatography-mass spectrometry-based proteomic analysis with data-independent acquisition quantified 510 proteins and 7019 peptides in the serum of patients. Alterations in the serum proteome reflect COVID-19 outcomes in patients treated with tocilizumab. Our results suggested that circulating proteins associated with the most significant prognostic impact belonged to the complement system, platelet degranulation, acute-phase proteins, and the Fc-epsilon receptor signaling pathway. Among these, upregulation of the complement system by activation of the classical pathway was associated with poor response to tocilizumab, and upregulation of Fc-epsilon receptor signaling was associated with lower mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michot</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3482-3331</Identifier><AffiliationInfo><Affiliation>Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dozio</LastName><ForeName>Vito</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Biognosys, Wagistrasse 21, Schlieren 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohmer</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, Hôpital Foch, Suresnes 92150, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pommeret</LastName><ForeName>Fanny</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département de Médecine, Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roumier</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, Hôpital Foch, Suresnes 92150, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Haochen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Biognosys, Wagistrasse 21, Schlieren 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sklodowki</LastName><ForeName>Kamil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biognosys, Wagistrasse 21, Schlieren 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danlos</LastName><ForeName>François-Xavier</ForeName><Initials>FX</Initials><AffiliationInfo><Affiliation>Département de Médecine, Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouali</LastName><ForeName>Kaissa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Département de Médecine, Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kishazi</LastName><ForeName>Edina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biognosys, Wagistrasse 21, Schlieren 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naigeon</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université Paris Saclay, Faculté de Pharmacie, Chatenay-Malabry F-92296, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griscelli</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département de biologie et pathologie, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gachot</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unité de Pathologie Infectieuse, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groh</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, Hôpital Foch, Suresnes 92150, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacciarello</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Département de Médecine, Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoclin</LastName><ForeName>Annabelle</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unité de Pathologie Infectieuse, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willekens</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Département d'hématologie, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakkal</LastName><ForeName>Madona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayle</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zitvogel</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silvin</LastName><ForeName>Aymeric</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soria</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université Paris Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barlesi</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département de Médecine, Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beeler</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biognosys, Wagistrasse 21, Schlieren 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>André</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département de Médecine, Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université Paris Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unité INSERM U981, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasse</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Université Paris Saclay, Faculté de Pharmacie, Chatenay-Malabry F-92296, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de biologie clinique, Hôpital Foch, Suresnes 92150, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unité INSERM U1176, Le Kremlin-Bicêtre, Université Paris Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaput</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ackermann</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, Hôpital Foch, Suresnes 92150, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escher</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biognosys, Wagistrasse 21, Schlieren 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marabelle</LastName><ForeName>Aurélien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif 94800, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université Paris Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre d'investigation clinique - biothérapie, INSERM CICBT1428, Villejuif 94800, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Proteome Res</MedlineTA><NlmUniqueID>101128775</NlmUniqueID><ISSNLinking>1535-3893</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anti-interleukin 6 receptor therapy</Keyword><Keyword MajorTopicYN="N">calprotectin</Keyword><Keyword MajorTopicYN="N">candidate proteins</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword><Keyword MajorTopicYN="N">thrombospondin-1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39352225</ArticleId><ArticleId IdType="doi">10.1021/acs.jproteome.2c00422</ArticleId></ArticleIdList></PubmedData></PubmedArticle>